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Introduction: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by
an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release
of interleukin-15 (IL-15), in the present study we investigated the role played by IL-15 in HER2/neu driven mammary
carcinogenesis and in its immunoprevention.
Methods: HER2/neu transgenic mice with homozygous knockout of IL-15 (here referred to as IL15KO/NeuT mice)
were compared to IL-15 wild-type HER2/neu transgenic mice (NeuT) regarding mammary carcinogenesis, profile of
peripheral blood lymphocytes and splenocytes and humoral and cellular responses induced by the vaccine.
Results: IL15KO/NeuT mice showed a significantly earlier mammary cancer onset than NeuT mice, with median
latency times of 16 and 20 weeks respectively, suggesting a role for IL-15 in cancer immunosurveillance. Natural
killer (NK) and CD8+ lymphocytes were significantly lower in IL15KO/NeuT mice compared to mice with wild-type
IL-15. The IL-12-adjuvanted allogeneic HER2/neu-expressing cell vaccine was still able to delay mammary cancer
onset but efficacy in IL-15-lacking mice vanished earlier: all vaccinated IL15KO/NeuT mice developed tumors within
80 weeks of age (median latency of 53 weeks), whereas more than 70 % of vaccinated NeuT mice remained tumor-free
up to 80 weeks of age. Vaccinated IL15KO/NeuT mice showed less necrotic tumors with fewer CD3+ lymphocyes
and lacked perforin-positive infiltrating cells compared to NeuT mice. Concerning the anti-vaccine antibody response,
antibody titer was unaffected by the lack of IL-15, but less antibodies of IgM and IgG1 isotypes were found in IL15KO/
NeuT mice. A lower induction by vaccine of systemic interferon-gamma (IFN-γ) and interleukin-5 (IL-5) was also observed
in IL15KO/NeuT mice when compared to NeuT mice. Finally, we found a lower level of CD8+ memory cells in the
peripheral blood of vaccinated IL15KO/NeuT mice compared to NeuT mice.
Conclusions: We demonstrated that IL-15 has a role in mammary cancer immunosurveillance and that IL-15-regulated
NK and CD8+ memory cells play a role in long-lasting immunoprevention, further supporting the potential use of IL-15
as adjuvant in immunological strategies against tumors.* Correspondence: carla.degiovanni@unibo.it
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Activation of the immune system to prevent onset and
progression of tumors not caused by infective agents is
emerging as a feasible perspective. Targeted immunopre-
vention was in fact obtained in mouse models, the most
studied of which consists in HER2/neu-transgenic mice
[1]. Vaccination of BALB/c mice transgenic for rat
HER2/neu (NeuT mice) with an interleukin-12 (IL-12)-
adjuvanted allogeneic HER2/neu-expressing cell vaccine
gave an effective and long-lasting prevention of mam-
mary carcinogenesis, provided that vaccinations started
at the preneoplastic stage and were repeated cyclically
for the mouse’s lifetime [2, 3]. Identification of immune
mechanisms at the basis of vaccine efficacy is important
to move toward clinical application and to optimize the
vaccine (e.g., with a choice of new adjuvants).
Recently, it has been reported that IL-12 can induce
a rapid release of interleukin-15 (IL-15) by tumor-
associated and tumor-infiltrating macrophages [4, 5].
Such induction is transient but is necessary to favor
infiltration of tumors by leukocytes and for the antitu-
mor and antimetastatic effects exerted by IL-12 [5]. In
addition interferon-γ (IFN-γ), the main mediator of the
activities of IL-12, can also induce IL-15 [6]. Thus we
hypothesized that the IL-12-adjuvanted cell vaccine
might induce IL-15, which in turn might have a role in
cancer immunoprevention.
IL-15 belongs to the four α-helix bundle cytokine fam-
ily and has some overlapping activities with interleukin-2
(IL-2). It signals through a heterotrimeric receptor com-
plex composed of the shared IL-2/15Rβ (CD122) and
common γ chain (γC) and a specific α subunit (IL-15Rα).
IL-15 is necessary for the development and function of
CD8+ T lymphocytes, natural killer (NK) cells, invariant
NKT cells and a subset of intestinal intraepithelial lym-
phocytes [7, 8]. IL-15 can exert antitumor and antimeta-
static activities [9–11] and IL-12 and IL-15 can act
synergistically to induce antitumor immune responses
[12]. Due to its promising antitumor activities, IL-15 is
currently being evaluated in some clinical trials for
advanced and metastatic tumors [13].
Here we studied the role played by IL-15 in HER2/
neu-driven mammary carcinogenesis and immunopre-
vention, through mice knocked out for the IL-15 gene
and transgenic for the HER2/neu oncogene. Mammary
carcinogenesis and efficacy of cancer immunopreven-
tion, and immune mechanisms, were studied in IL15-
deficient and IL15-proficient NeuT mice.
Methods
Mice
Mice knocked out for the IL-15 gene and transgenic for
the transforming activated rat HER2/neu oncogene
driven by the mouse mammary tumor virus promoter,on a BALB/c background (throughout referred to as
IL15KO/NeuT mice) were kindly provided by Dr. Silvia
Bulfone Paus (Faculty of Human and Medical Sciences,
University of Manchester, Manchester, UK and Department
of Immunology and Cell Biology, Research Center Borstel,
Borstel, Germany). NeuT mice and IL15KO/NeuT mice
were bred in the local animal facility. Animal experiments
were authorized by the Ethical Scientific Committee for
Animal Experimentation of the University of Bologna
(Bologna, Italy). Mammary pads were inspected weekly:
masses with a mean diameter exceeding 3 mm were con-
sidered tumors. Mice were sacrificed when tumors were
present in all mammary glands or when a single mass
exceeded a mean diameter of 1.5 cm.
Vaccination
Mice were vaccinated lifelong with allogeneic (H-2q)
murine mammary carcinoma cells expressing high levels
of HER2/neu and transduced with IL-12 genes [3],
starting at the sixth week of age. Vaccine cells were
proliferation-blocked by treatment with mitomycin C
(40 μg/ml Sigma-Aldrich, Milan, Italy) and administered
intraperitoneally in 0.4 ml of phosphate-buffered saline
(PBS) (Invitrogen, Milan, Italy). Control mice received
PBS alone. The vaccination schedule was reported previ-
ously: twice weekly for 2 weeks, followed by 2 weeks of
rest [3]. Mice were monitored weekly for tumor occur-
rence. Tumor progression of control mice was equal to
that of untreated mice.
Immunophenotyping
Blood was collected in EDTA tubes (BD Pharmingen,
San Diego, CA, USA) and leukocytes counted in a
Neubauer hemocytometer using Turk’s solution (Merck
KGaA, Darmstadt, Germany). Lymphocytes and granu-
locytes were distinguished by morphology of nuclei.
After lysis of red blood cells, FcγII and FcγIII receptors
were blocked with anti-CD16/CD32 antibodies at 5 μg/ml
(Mouse BD Fc Block™, BD Pharmingen) then specific
primary antibodies were added: fluorescein isothiocyanate
(FITC)-conjugated rat anti-mouse CD45R/B220 monoclo-
nal antibody; phycoerythrin (PE)-conjugated hamster anti-
mouse CD3e monoclonal antibody; PE-conjugated rat
anti-mouse CD335 (NKp46) monoclonal antibody; FITC-
conjugated rat anti-mouse CD49b (clone DX5) monoclo-
nal antibody; FITC-conjugated rat anti-mouse CD8a
monoclonal antibody; PE-conjugated rat anti-mouse CD4
monoclonal antibody; PE-conjugated rat anti-mouse
CD44 monoclonal antibody. All antibodies were from BD
Pharmingen. The Partec CyFlow® space cytofluorimeter
was used and analysis was performed with Windows™
FloMax® software. Through backgating from the CD3+
and B220+ clusters, we selected the lymphocyte gate
in the FSC-SSC dot plot. At least 10,000 events were
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stant in the various experiments. The same reagents and
procedures were used for splenocyte immunophenotyping.
RNA extraction and real-time PCR
RNA was extracted from frozen mammary glands
with Trizol reagent (Life Technologies, Milan, Italy).
Rat HER2/neu expression was quantified by real-time
PCR as previously reported [14]. NKp46, CD8 and
CD4 expression was determined by real-time PCR using
the PrimePCR SYBR Green Assays (qMmuCID0015089,
qMmuCID0016523, qMmuCID0022320 respectively,
Bio-Rad, Milan, Italy) following the instruction man-
ual. GAPDH was used as the housekeeping gene
(qMmuCED0027497, Bio-Rad).
Quantification of cytokines
Levels of cytokines in plasma were measured using the
Bio-Plex™ Mouse Cytokine 23-Plex bead assay (Bio-Rad)
following the manufacturer’s instructions. Production of
IFN-γ in culture supernatants was quantified by enzyme-
linked immunosorbent assay (ELISA) (Quantikine Mouse
IFN-γ, R&D Systems, Minneapolis, MN, USA). Levels of
the bioactive IL-15 were measured in serum with the
Mouse IL-15/IL-15R Complex ELISA Ready-SET-Go
(eBioscience, San Diego, CA, USA). We set up a standard
curve of nine points by twofold serial dilutions of the top
standard and we performed an overnight incubation at
4 °C of the samples to reach the maximal sensitivity.
Serum samples were diluted 20 times with assay buffer.
Mixed lymphocyte-tumor cell cultures
Mononuclear cells were obtained from spleens using cell
strainers with 40 μm pores (Falcon, Oxnard, CA, USA).
After lysis of red blood cells, splenocytes were co-
cultured at a 10:1 ratio with proliferation-blocked
mammary carcinoma cells for 6 days in RPMI 1640
supplemented with 10 % fetal bovine serum and with
10 units/ml of recombinant IL-2 (Peprotech, Rocky Hill,
NJ, USA). Splenocytes yields were determined by count-
ing with a Neubauer’s hemocytometer (viable and dead
cells were counted separately using the erythrosine dye
exclusion method).
Antibody response
Mice were bled from the ventral caudal vein and sera
were stored frozen at –80 °C. To determine the level of
anti-vaccine antibodies, sera were used in an indirect
immunofluorescence assay to stain viable vaccine cells
followed by cytofluorometric analysis as previously
described [3]. Sera were diluted 1:65. To detect total
anti-vaccine immunoglobulin (Ig)Gs, F(ab’)2 fragments
of goat anti-mouse IgGs (H+L) labeled with Alexa Fluor®
488 (20 μg/ml, Life Technologies) were used as secondaryantibodies. To detect specific antibody isotypes FITC-
conjugated rat anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG3
(50 μg/ml, BD Pharmingen™) were used. The intensity of
fluorescence of each serum sample was normalized to the
expression of rat HER2/neu by the target cells (determined
using the monoclonal antibody Ab4, clone 7.16.4, 5 μg/ml,
Oncogene Research Products, Cambridge, MA, USA).
Morphologic and immunohistochemical analyses
Whole mounts were prepared as previously described
[15]. Mammary tumors were fixed in formalin and embed-
ded in paraffin. Hematoxylin and eosin staining (H&E)
was used to assess histology. Infiltration by CD3+ and
perforin-positive cells was determined through immuno-
histochemistry with anti-CD3 (Ab828; Abcam, Cambridge,
UK) and anti-perforin (Ab16074, Abcam) antibodies as
previously described [16]. Immunostaining was devel-
oped using alkaline phosphatase-conjugated streptavi-
din (Thermo Fisher Scientific, Waltham, MA, USA)
and vulcan fast red chromogen (Biocare Medical,
Concord, CA, USA). Slides were counterstained with
hematoxylin (BioOptica, Milan, Italy) and images were ac-
quired by Leica DMRD optical microscope (Leica, Milton
Keynes, UK).
Statistical analysis
Differences in tumor-free survival curves were analyzed
by the Mantel-Haenszel test. Cytokine, cell frequency,
real-time PCR data and antibody levels were compared
by the Student’s t test or nonparametric Wilcoxon test.
Results
Lack of IL-15 hastens HER2/neu-driven mammary
carcinogenesis
Mice knocked out for IL-15 and transgenic for HER2/
neu oncogene (IL15KO/NeuT mice) developed mam-
mary carcinomas with a median latency of 16 weeks, sig-
nificantly shorter than the median latency of 20 weeks
displayed by HER2/neu transgenic mice with wild-type
IL-15 (NeuT mice) (Fig. 1a). Mammary carcinogenesis
was thus earlier in the absence of IL-15 indicating a role
in immunosurveillance for this cytokine. To confirm at
the molecular level that the absence of IL-15 induced an
earlier mammary carcinogenesis, we evaluated the ex-
pression of HER2/neu oncogene in mammary glands
from 6-week-old mice. HER2/neu is the driving force of
carcinogenesis in this tumor model, thus its expression
can be considered as a molecular marker of tumor pro-
gression. IL15KO/NeuT mice showed a higher expres-
sion of HER2/neu transgene in preneoplastic mammary
tissue compared to IL-15 wild-type NeuT mice (Fig. 1b).
This data is consistent with the greater number of
preneoplastic/neoplastic cells in mammary glands of
IL15KO/NeuT mice, compared to NeuT mice, observed
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Fig. 1 Earlier mammary carcinogenesis in IL15KO/NeuT mice. a Tumor-free survival curves (IL15KO/NeuT mice versus NeuT mice, p <0.01 by the
Mantel-Haenszel test). IL15KO/NeuT mice: n = 46; NeuT mice: n = 117. b Expression of rat HER2/neu transcript in preneoplastic mammary glands
from 6-week-old mice. Expression was evaluated by real-time PCR applying the ΔΔCt method using GAPDH as the housekeeping gene and the
HER2/neu-positive TUBO mammary carcinoma cell line as reference. c Whole mounts of mammary glands obtained from 15-week-old mice.
N = lymph node. d Expression of NKp46 and CD8 mRNAs in preneoplastic mammary glands from 6-week-old mice. Expression was evaluated by
real-time PCR applying the ΔΔCt method using GAPDH as the housekeeping gene and mammary glands from 6-week-old BALB/c mice
as reference. * = p <0.05 at Student’s t test. IL15KO/NeuT BALB/c mice transgenic for rat HER2/neu oncogene and knocked out for IL-15,
NeuT BALB/c mice transgenic for rat HER2/neu oncogene
Croci et al. Breast Cancer Research  (2015) 17:70 Page 4 of 13in whole mounts of inguinal mammary glands from 15-
week-old mice (Fig. 1c), and confirms the more preco-
cious onset of preneoplastic/neoplastic HER2/neu-
positive cells.
Lack of IL-15 impairs the efficacy of cancer preventive
vaccine
In NeuT mice an IL-12-adjuvanted allogeneic HER2/
neu-expressing cell vaccine, repeatedly administered,
was found to delay mammary cancer onset, leading to a
more than doubled mice lifetime expectancy [2, 3]. We
tested the efficacy of this vaccine in the IL15KO/NeuT
mice. The preventive vaccine effectively delayed mam-
mary carcinogenesis also in IL15KO/NeuT mice but
immunoprevention did not last as long as in NeuT mice.
At 80 weeks of age all IL15KO/NeuT mice had devel-
oped tumors, while about 70 % of NeuT mice were still
free from mammary carcinomas (p <0.01 between the
tumor-free survival curves) (Fig. 2a). Moreover, the
mean number of tumors per mouse was higher in
IL15KO/NeuT mice at sacrifice compared to NeuT mice
(Fig. 2b) further sustaining a role for IL-15 in immuno-
prevention. There is increasing evidence that IL-15 is
only secreted in complex with its unique receptor, IL-
15Rα [17]. Vaccinated NeuT mice showed higher levelsof IL-15/IL-15Rα heterodimers in serum than untreated
NeuT mice (Fig. 2c) indicating that the IL-12-expressing
vaccine can induce IL-15 in its bioactive form. Instead,
IL15KO/NeuT mice had levels of the IL-15/IL-15Rα
complex lower than the limit of detection of the ELISA
(Fig. 2c).
Immunological pathways regulated by IL-15
The lack of IL-15 caused an earlier mammary carcino-
genesis and an earlier loss of efficacy of the preventive
vaccine. To identify the immune mechanisms involved
in these phenomena, we immunophenotyped peripheral
blood lymphocytes and splenocytes from NeuT versus
IL15KO/NeuT control and vaccinated mice. The kinetic
study of humoral and cellular responses elicited by
vaccine was performed at several time points during vac-
cination cycles, after one, two and three vaccination cy-
cles in comparison with age-matched controls (7, 11 and
15 weeks of age respectively) and after six and ten vac-
cination cycles (29 and 42 weeks of age) only in vacci-
nated mice, since at these time points untreated mice
developed tumors and had to be sacrificed.
In naive mice, IL-15 deficiency did not modify the
level of circulating leukocytes (see Additional file 1)
but had a significant impact on lymphocyte subsets.
Fig. 2 Impaired immunoprevention of mammary carcinogenesis in IL15KO/NeuT mice. Vaccinated mice received a lifelong IL-12-adjuvanted allogeneic
HER2/neu-expressing cell vaccine, as described in “Material and methods”. Control mice received PBS. Control mice are the same reported in Fig. 1 and
are shown here for comparison. a Tumor-free survival curves (IL15KO/NeuT mice versus NeuT mice, p <0.01 by the Mantel-Haenszel test). Vaccinated
IL15KO/NeuT mice: n = 24; vaccinated NeuT mice: n = 56. b Tumor multiplicity is shown as mean ± SEM. c Serum levels of the bioactive IL-15/IL-15Rα
determined 20 hours after vaccination in mice of 11 weeks of age by ELISA. The dotted line indicates the sensitivity of the assay. ELISA enzyme-linked
immunosorbent assay, IL-15 interleukin 15, IL15KO/NeuT BALB/c mice transgenic for rat HER2/neu oncogene and knocked out for IL-15, NeuT BALB/c
mice transgenic for rat HER2/neu oncogene, PBS phosphate-buffered saline, SEM standard error of the mean
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absolute number (see Additional file 2) of NK and CD8+
cells in peripheral blood. Spleen cell yield from IL15KO/
NeuT mice was lower than that of NeuT mice (see
Additional file 3, 15-week-old control mice) and fre-
quency (Fig. 4) as well as absolute number (see Additional
file 3) of NK and CD8+ spleen lymphocytes were signifi-
cantly decreased in IL-15-lacking mice. In addition,
IL15KO/NeuT mice showed 1000-fold lower expression of
NKp46 and CD8 genes in preneoplastic mammary glands
compared to NeuT mice (Fig. 1d).
Vaccination of IL-15-proficient NeuT mice caused a
significant and persistent decrease in the percentage and
in the absolute number of NK cells in peripheral blood
and in spleen (compare control and vaccinated NeuT
mice in Figs. 3 and 4 and see Additional files 2 and 3).
Moreover, at 42 weeks of age vaccinated NeuT mice
showed a significant decrease in circulating lymphocyte
concentration (see Additional file 1) and in spleen yield
(see Additional file 3) with a parallel increase in the per-
centage of B lymphocytes and a decrease in the percent-
age of CD3+, CD4+, CD8+ T lymphocytes (Figs. 3 and 4,
comparison: 15- versus 42-week-old NeuT mice). There-
fore the number of T cells decreased more than that of B
and NK cells during the time course of vaccination.
In IL15KO/NeuT mice vaccination induced transient
alterations of circulating populations: higher B lymphocyteand lower CD4+ and CD8+ T lymphocyte percentages
were observed in comparison to both IL15KO/NeuT con-
trols and to vaccinated NeuT mice after the first vaccin-
ation cycle (7-week-old mice) (Fig. 3). Lifelong vaccination
did not modify NK and CD8+ levels of IL15KO/NeuT
mice, which remained significantly lower than in vacci-
nated NeuT mice up to 42 weeks (Figs. 3 and 4).
Proven mechanisms at the basis of the efficacy of
the preventive vaccine in NeuT mice were the induc-
tion of a fast and sustained antibody response against
the HER2/neu oncoantigen and the release of IFN-γ
[2, 3, 15, 18]. In IL15KO/NeuT mice the vaccine in-
duced a faster antibody response after the first vac-
cination cycle, then antibodies reached plateau levels
similar to those of NeuT mice (Fig. 5a). However,
differences in the antibody isotypes were found. Spe-
cifically less IgM and IgG1 were detected in IL15KO/
NeuT mice (Fig. 5b).
To analyze the activation of cell-mediated immunity,
we co-cultured splenocytes from vaccinated mice with
syngeneic neu-expressing cells and we determined
lymphocyte yield and production of IFN-γ, the main
mediator of the activities of IL-12, after 6 days of co-
cultures. The presence of HER2/neu antigen effect-
ively stimulated the splenocytes: about a twofold in-
crease in cell yield and in IFN-γ production was


































































































Fig. 3 Relative frequency of peripheral blood lymphocyte subsets in IL-15-deficient and IL-15-proficient, control and vaccinated NeuT mice. Lymphocyte
subsets were analyzed by flow cytometry in control and vaccinated mice 20 hours after vaccination. A lymphocyte gate was defined in the FSC-SSC dot
plot then the percentage of B220+, CD3+, CD4+, CD8+ and Nkp46 and DX5 double-positive cells was determined. Significance of comparisons (Student’s
t test): *p <0.05, IL15KO/NeuT versus NeuT mice; #p <0.05, vaccinated versus control mice within the same strain. Mean ± SEM is shown (three to five mice
per group). IL15KO/NeuT BALB/c mice transgenic for rat HER2/neu oncogene and knocked out for IL-15, NeuT BALB/c mice transgenic for rat HER2/neu
oncogene, SEM standard error of the mean
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cultures from IL-15 knockout mice was equal to that
of splenocytes cultures from wild-type mice at 15
weeks of age but at later time points (42 weeks of age)
it was lower (Fig. 5c). Nevertheless concentration of
IFN-γ in supernatants was comparable between the
two mouse strains both at 15 and 42 weeks of age
(Fig. 5d).Vaccinated IL-15-deficient NeuT mice had less mem-
ory CD8+ lymphocytes in peripheral blood compared to
vaccinated IL-15 wild-type NeuT mice (Fig. 6).
The concentration of a panel of cytokines in plasma
from IL-15-deficient and IL-15-proficient NeuT mice
20 hours after vaccine administration was studied and
compared to those of corresponding untreated controls
(see Additional file 4). A rise in IFN-γ and IL-5 was
Fig. 4 Relative frequency of spleen lymphocyte subsets in IL-15-deficient and IL-15-proficient, control and vaccinated NeuT mice. Splenocytes were
analyzed by flow cytometry in control and vaccinated mice. The percentage of B220+, CD3+, CD4+, CD8+ and Nkp46 and DX5 double-positive cells
is reported. Significance of comparisons (Student’s t test): *p <0.05, IL15KO/NeuT versus NeuT mice; #p <0.05, vaccinated versus control mice within
the same strain; §p <0.05, 15- versus 42-week-old mice within the same strain. Mean ± SEM is shown (three to six mice per group). IL15KO/NeuT
BALB/c mice transgenic for rat HER2/neu oncogene and knocked out for IL-15, NeuT BALB/c mice transgenic for rat HER2/neu oncogene,
SEM standard error of the mean
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mice. Several cytokines were similarly modified by the
vaccine in IL-15-deficient and IL-15-proficient NeuT
mice, with a significant rise in interleukin-1 alpha (IL-
1α), regulated on activation, normal T cell expressed and
secreted (RANTES), interleukin-13 (IL-13), monocyte
chemoattractant protein-1 (MCP-1) and macrophage
inflammatory protein-1 alpha (MIP-1α) and a decrease
in granulocyte macrophage-colony stimulating factor
(GM-CSF). Untreated IL-15-deficient NeuT mice showed
higher levels of granulocyte colony-stimulating factor
(G-CSF) and keratinocyte-derived chemokine (KC)
and lower levels of RANTES and interleukin-17 (IL-17)
than IL-15-proficient NeuT mice. In IL-15KO/NeuT mice
the vaccine induced a rise in RANTES, IL-17 and KC
reaching levels similar to those of IL-15 wild-type NeuT
mice (see Additional file 4).
Recruitment of immune cells in mammary tissue
by vaccination
Tumors from vaccinated versus untreated IL-15-deficient
and IL-15-proficient NeuT mice were analyzed formorphology and infiltrating CD3+ and perforin-positive
cells. Tumors from vaccinated NeuT mice showed several
necrotic areas, which were rarely present in tumors from
vaccinated IL15KO/NeuT mice as well as in untreated
mice (Fig. 7, H&E). Vaccination induced in NeuT mice a
high level of infiltrated CD3+ lymphocytes within the
tumor mass and in intra- and peritumoral stroma (Fig. 7),
which was not elicited in IL15KO/NeuT mice. The few
CD3+ lymphocytes infiltrating IL15KO/NeuT tumors
were found mainly within the tumor stroma (Fig. 7).
Tumors from NeuT mice showed few perforin-positive
cells, slightly more numerous in tumors from vaccinated
mice. Instead, tumors from IL15KO/NeuT mice (both
untreated and vaccinated) did not show any perforin-
positive cells (Fig. 7). To determine whether the vaccine
could induce the recruitment of immune cells at the site
of carcinogenesis, we investigated by real-time PCR the
expression of NKp46, CD8 and CD4 mRNAs in tumor-
free mammary glands from 26-week-old vaccinated
NeuT mice compared to that in preneoplastic mammary
glands from untreated NeuT mice at 6 weeks of age,
at the baseline of vaccination. NKp46 levels were
Fig. 5 Immune mechanisms induced by the preventive vaccine in IL15KO/NeuT and NeuT mice. a Anti-vaccine antibodies. Sera from vaccinated
mice were tested against vaccine cells by indirect immunofluorescence followed by cytofluorometric analysis. b Anti-vaccine cell antibody
isotypes. Mean ± SEM is shown (eight mice per group). c Yield of splenocyte cultures from 15- and 42-week-old vaccinated mice (IL15KO/NeuT
versus NeuT) restimulated by the 6-day co-culture with HER2/neu-expressing syngeneic cells. d IFN-γ production by splenocytes restimulated
as in c. Mean ± SEM is shown (three to six mice per group). *p <0.05 by the Student’s t test. IFN-γ interferon-gamma, IL15KO/NeuT BALB/c mice
transgenic for rat HER2/neu oncogene and knocked out for IL-15, NeuT BALB/c mice transgenic for rat HER2/neu oncogene, SEM standard error
of the mean
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nated mice, whereas CD8 and CD4 levels were com-
parable (Fig. 8). Tumors from untreated mice showed
a decreased expression of CD8 and CD4 and a simi-
lar expression of NKp46 compared to preneoplastic
mammary glands (Fig. 8). Finally, NKp46, CD8 and
CD4 levels were significantly higher in mammary
glands of 26-week-old vaccinated mice with respect to the
tumor area of untreated 26-week-old mice (Fig. 8).
Discussion
We found that IL-15 promotes immunosurveillance of
mammary carcinogenesis in a transgenic mouse model
driven by the activation of HER2/neu oncogene. In
addition, we demonstrated that lack of this cytokine
caused alterations in immune populations and in vaccine
efficacy, showing that IL-15 and/or its regulated popula-
tions are necessary for long-term cancer immunopreven-
tion induced by an IL-12-adjuvanted allogeneic HER2/
neu-expressing cell vaccine. Lack of IL-15 affected theimmune system: transgenic mice deficient for IL-15
showed a lower percentage and a lower number of NK
cells (defined as NKp46+DX5+ cells in the lymphocyte
gate according to Walzer et al. [19]) and CD8+ T
lymphocytes in peripheral blood and in spleen compared
to IL-15-proficient mice. Similar alterations in lympho-
cyte subsets were reported also by Kennedy and co-
workers in mice with a different background (C57BL/6
mice [20]) indicating a key role of IL-15 in the regula-
tion of development, survival and differentiation of NK
cells and CD8+ T lymphocytes.
IL-15-deficient HER2/neu transgenic mice showed an
earlier mammary carcinogenesis, with median latency
time of tumor onset 4 weeks before that of IL-15-
proficient NeuT mice, suggesting a role for IL-15 in
tumor immunosurveillance. A potential role of IL-15 in
tumor immunosurveillance has also recently been re-
ported in a mouse model of lymphoma [21]. The above-
mentioned immune defects, occurring downstream of
IL-15 deficiency, might be at the basis of the decreased
Fig. 6 Memory CD8+ T cells at late phases of vaccination. Memory
CD8+ T cells were defined as CD44high by flow cytometry.
Percentage of CD8+CD44high lymphocytes is reported. *p <0.05 by
the Student’s t test
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NeuT mice knocked out for the perforin gene, which is
mainly expressed by NK and CD8+ T lymphocytes, simi-
larly showed a quicker mammary carcinogenesis [22]. A
faster onset of mammary carcinomas and a greater
tumor multiplicity were found in NeuT mice after deple-
tion of NK cells (by treatment with anti-asialo GM1),
but not after depletion of CD8+ cells [22]. Finally, it has
been recently demonstrated that the adaptive immune
system exerts neither protective nor promoting activities
during mammary carcinogenesis and spontaneous me-
tastasis formation in HER2/neu transgenic mice [23].
Taken together, these data point out NK cells as candi-
date effectors cells of tumor immunosurveillance in this
model.
Activities of IL-15 at homeostasis have been exten-
sively studied, whereas its functions during immune acti-
vation are not clearly defined. Data presented in this
manuscript support a role for IL-15 in cancer immuno-
prevention. In the absence of IL-15 the preventive vac-
cine significantly delayed tumor onset but all mice
developed tumors with a greater multiplicity. Three phe-
nomena might contribute to the decreased efficacy of
the vaccination: (1) quicker mammary carcinogenesis
due to the impaired immunosurveillance; (2) absence of
direct effects of IL-15; (3) deficit of immune effectors as
a consequence of the absence of IL-15. We discuss the
three topics below.
In NeuT mice vaccines were more effective when
started in preneoplastic stage, corresponding to 6 weeks
of age [18]. IL15KO/NeuT mice showed a quickercarcinogenesis and a higher level of HER2/neu oncogene
in mammary glands when vaccination started, therefore,
this might contribute to decreased vaccine efficacy.
Direct administration of IL-15 has shown antitumor
effects in several preclinical mouse tumor models [11].
IL-15 has chemotactic activities and can promote adhe-
sion of leukocytes to vascular endothelial cells [24].
Therefore, in the absence of IL-15, there might be less
recruitment of leukocytes in tumor lesions thus decreas-
ing vaccine efficacy. We documented here for the first
time that in NeuT mice the preventive vaccine induced
a significant decrease in the percentage and in the num-
ber of NK cells in peripheral blood and in spleen, and of
CD8+ lymphocytes in peripheral blood. A possible ex-
planation is that NK and CD8+ cells are recruited in
other tissues (e.g., mammary glands where carcinogen-
esis takes place) where they can exert immune effector
functions. In fact, we showed that NKp46 levels were
significantly higher in tumor-free mammary glands from
vaccinated mice compared to those of preneoplastic
mammary glands from untreated mice, whereas CD8
and CD4 levels were comparable, indicating that the
vaccine can induce the recruitment of NK cells in mam-
mary tissue.
Similarly to vaccinated NeuT mice, administration
of recombinant human (rh)IL-12 in cancer patients
(intravenous [25], intratumoral [26], subcutaneous
[27]) induced a dose-dependent lymphopenia starting
some hours after the injections and lasting several
days. All lymphocyte subsets were affected but NK cells
were the most affected ones. It was hypothesized that
such lymphopenia derived from the activation of lym-
phocytes, with their subsequent extravasation and re-
distribution to tumors and lymphoid organs. Moreover,
lymphopenia was also hypothesized to be the result of
secondary cytokines produced in response to rhIL-12
[25]. We demonstrated that the IL-12-based vaccine in-
duced the production of IL-15, therefore, IL-15 could
be a secondary cytokine cooperating to vaccine efficacy.
Interestingly, intravenous administration of rhIL-15 in
patients with cancer was also found to induce a rapid
reduction (within 40 minutes) in peripheral blood NK
cells, apparently due to redistribution, followed by
normalization of cell numbers over 3 days. Chronic ad-
ministration of rhIL-15 subsequently led to an increase
in NK cells by hyperproliferation [28]. Simultaneous
administration of IL-12 and IL-15 might thus have syner-
gistic effects on NK cells and might be promising to in-
duce antitumor immunity.
Tumors from vaccinated NeuT mice showed several
necrotic areas and infiltrating CD3+ lymphocytes, rarely
detected in tumors from IL15KO/NeuT mice as well as
from untreated NeuT mice. Furthermore, tumors from
vaccinated NeuT mice showed few perforin-positive
Fig. 8 Infiltrating lymphocytes in mammary glands and tumors from NeuT mice. Levels of NKp46, CD8 and CD4 transcripts were quantified by
real-time PCR in preneoplastic mammary tissue from 6-week-old untreated NeuT mice, tumors from 26-week-old untreated NeuT mice and
tumor-free mammary glands from 26-week-old vaccinated NeuT mice. The ΔΔCt method was applied using GAPDH as the housekeeping gene
and mammary glands from 6-week-old BALB/c mice as reference. * = p <0.05 at Student’s t test, ns = not significant. IL15KO/NeuT BALB/c mice











































Fig. 7 Morphology and infiltration by CD3+ and perforin + lymphocytes in tumors of control and vaccinated IL15KO/NeuT and NeuT mice. Morphology
was evaluated by staining with H&E. Presence of CD3+ and perforin-producing cells was evaluated by IHC with a chromogenic reaction. H&E hematoxylin
and eosin, IHC immunohistochemistry, IL15KO/NeuT BALB/c mice transgenic for rat HER2/neu oncogene and knocked out for IL-15, NeuT BALB/c mice
transgenic for rat HER2/neu oncogene
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IL15KO/NeuT mice. Immunohistochemical analyses
previously performed in tumors from NeuT mice
(control, IL-12 treated and vaccine treated) showed a
huge infiltrate of CD8+ lymphocytes, NK cells, dendritic
cells, macrophages and neutrophils in tumors from vac-
cinated mice supporting this hypothesis [2]. The number
of CD8+ lymphocytes, NK cells and dendritic cells in-
creased also in tumors of mice treated with IL-12 alone
indicating that recruitment of that type of immune cells
is mediated by IL-12 [2].
The efficacy of the preventive vaccine has been dem-
onstrated to rely on the induction of a fast and sustained
antibody response against the HER2/neu oncoantigen
and on the release of IFN-γ [2, 3, 15, 18]. In IL15KO/
NeuT mice the vaccine induced a faster B cell response
and a titer of antibody against vaccine cells equal to that
induced in IL-15-proficient NeuT mice. Nevertheless,
IL15KO/NeuT mice had less IgM and IgG1 anti-vaccine
cell antibodies suggesting that antibodies of these iso-
types might have a role in long-term cancer immunopre-
vention. The antibody isotype, which has been mainly
associated with the efficacy of different kinds of anti-
HER2/neu vaccines, is IgG2a [15, 29–31]. To identify
immune mechanisms responsible for the efficacy of the
IL-12-adjuvanted allogeneic HER2/neu-expressing cell
vaccine, we previously vaccinated NeuT mice knocked
out for the Igμ-chain gene (NeuT-μMT). One-third of
NeuT-μMT mice was antibody-deficient and did not re-
spond to the vaccine, highlighting the key role of anti-
bodies in cancer immunoprevention in this model. Two-
thirds of NeuT-μMT mice, able to bypass the IgM
defect, produced high-titer anti-vaccine antibodies.
Nevertheless, these mice showed a partial response to
the vaccination with a median tumor latency of 45 weeks
and this could be related to a lower titer of IgM and
IgG1 antibodies against the vaccine compared to NeuT
mice [15]. Mouse IgMs can activate the complement
[32] while IgG1s can activate antibody-dependent cellu-
lar cytotoxicity (ADCC) via FcγRIII and can bind to
FcRn involved in the recycling of IgG and in the trans-
port of IgG-bound antigens favoring antigen presenta-
tion [33]. The lower production of anti-HER2/neu IgM
and IgG1 antibodies found in IL15KO/NeuT mice might
thus lead to a decreased activation of complement and
antigen presentation resulting in a partial loss of vaccine
efficacy. Indeed the complement has been recently
shown to be involved in immunosurveillance in NeuT
mice [34].
IFN-γ production following in vitro co-culture of sple-
nocytes of vaccinated IL15KO/NeuT mice with tumor
cells was comparable to that of vaccinated NeuT mice
suggesting that the ability of splenocytes to produce
IFN-γ was not affected by the lack of IL-15. Instead, thelevels of systemic IFN-γ reached 20 hours after vaccin-
ation were lower in IL-15-deficient mice, suggesting that
there were less cells that might respond to IL-12 com-
pared to NeuT mice. The most striking difference
between IL-15-deficient and IL-15-proficient mice
concerned NK cells, CD8+ T lymphocytes and CD8+
memory T cells. To date the induction of a cytotoxic
CD8+ T cell response by the preventive vaccine in
NeuT mice has been looked for but has never been
detected [2, 3, 15, 18]. We suggest that NK cells are
necessary to obtain a fully effective immunoprevention of
HER2/neu-driven mammary carcinogenesis. On the
contrary, Park et al. and Sakai et al. found that vac-
cine efficacy depends on the induction of anti-HER2/
neu antibodies but NK cells and ADCC are dispensable
[29, 35]. Such discrepancy could be mainly due to the
experimental model used to investigate mechanisms of
vaccine efficacy: in fact transplantable tumor models
(healthy BALB/c mice challenged with TUBO mammary
cancer cells) can elicit profoundly different immune
mechanisms than spontaneously arisen carcinogenesis
[36, 37]. Other differences concern the different types of
vaccines/vaccination protocol. As vaccine, Park et al.
used adenoviral vectors expressing the extracellular and
transmembrane domains of rat HER2/neu [29]; Sakai
et al. used dendritic cells infected with adenoviral vectors
expressing the extracellular and transmembrane domains
of rat HER2/neu [35] while we used IL-12-adjuvanted
vaccine based on allogeneic rat HER2/neu-expressing
cells [3].
To date NK cells have been evaluated as tools for
cancer immunotherapy (reviewed in [38]). Interestingly,
adoptive transfer of syngeneic NK cells preactivated with
IL-12/15/18 was effective in decreasing growth of estab-
lished tumors in mouse models [39] and IL-15 was
able to increase efficacy of cetuximab by activating
NK cells [40].
In line with our results, it has been recently shown
that including IL-15 in HER2/neu-based dendritic cell
vaccines and vaccines targeted to professional antigen-
presenting cells can increase vaccine efficacy [41, 42].
Moreover, TS/A breast and TRAMP-C2 prostate cancer
cells engineered to co-express IL-15 and IL-15Rα
showed a lower growth after subcutaneous injection in
syngeneic mice and were also effective as a vaccine acti-
vating immune responses (mainly mediated by CD8+
and NK cells), which delayed the growth of tumor cell
challenges [43].
Conclusions
Here, by exploiting mice knockout for IL-15, we formally
demonstrated for the first time that IL-15 sustains mam-
mary cancer immunosurveillance. In addition, we dem-
onstrated that an IL-12-based cell vaccine can induce
Croci et al. Breast Cancer Research  (2015) 17:70 Page 12 of 13IL-15 and that IL-15 is required for the complete effi-
cacy of the vaccine. IL-15 knockout mice had im-
munological defects in NK and CD8+ cells. These
findings increase the understanding of the relation-
ship between the immune system and mammary car-
cinogenesis, evidencing that mammary tumor onset
and long-lasting immunoprevention are controlled by
IL-15-mediated immune mechanisms involving in
particular NK and CD8+ memory cells. These results
support a potential use of IL-15 as an adjuvant in
vaccination approaches.
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Additional file 1: Figure S1. Concentration of peripheral blood
leukocytes, lymphocytes and granulocytes in IL-15-deficient and
IL-15-proficient, control and vaccinated NeuT mice.
Additional file 2: Figure S2. Concentration of peripheral blood
lymphocyte subsets in IL-15-deficient and IL-15-proficient, control
and vaccinated NeuT mice. To obtain the number of specific
lymphocyte populations, the percentage of B, T, CD4+, CD8+ and
NK cells determined by flow cytometry using a lymphocyte gate
was multiplied by the number of lymphocyte/ml. Significance of
comparisons (Student’s t test): *p <0.05, IL15KO/NeuT versus NeuT
mice; #p <0.05, vaccinated versus control mice within the same
strain. Mean ± SEM is shown (three to six mice per group).
Additional file 3: Figure S3. Spleen cell yield and splenocyte subset
yield of IL-15-deficient and IL-15-proficient, control and vaccinated, NeuT
mice. To obtain the absolute number of subsets of splenocytes, the
percentage of B, T, CD4+, CD8+ and NK cells determined by flow
cytometry was multiplied by the total number of splenocytes. Significance
of comparisons (Student’s t test): *p <0.05, IL15KO/NeuT versus NeuT mice;
#p <0.05, vaccinated versus control mice within the same strain; §p <0.05,
15 versus 42-week-old mice within the same strain. Mean ± SEM is shown
(three to six mice per group).
Additional file 4: Figure S4. Systemic cytokines induced by the
preventive vaccine in IL-15-deficient and IL-15-proficient NeuT mice.
Analyses were performed 20 hours after the administration of the
vaccine at the end of the third vaccination cycle (15-week-old mice).
Mean ± SEM is shown (five mice per group). Significance of comparisons
(Wilcoxon nonparametric test): *p <0.05, IL15KO/NeuT versus NeuT mice;
#p <0.05, vaccinated versus control mice within the same strain. Production
of IL-3 and IL-6 was not detected.
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